Effects of statin on plaque stability and thrombogenicity in hypercholesterolemic patients with coronary artery disease (Q44378566)

2 December 2017

title

Effects of statin on plaque stability and thrombogenicity in hypercholesterolemic patients with coronary artery disease (English)

1 reference

2 December 2017

0 references

Ji Won Son

1

1 reference

2 December 2017

Kwang Kon Koh

2

1 reference

2 December 2017

Jeong Yeal Ahn

3

1 reference

2 December 2017

Dong Kyu Jin

4

1 reference

2 December 2017

Gi Soo Park

5

1 reference

2 December 2017

Dae Sung Kim

6

1 reference

2 December 2017

Eak Kyun Shin

7

1 reference

2 December 2017

language of work or name

English

0 references

publication date

1 March 2003

1 reference

International Journal of Cardiology

2 December 2017

published in

1 reference

2 December 2017

volume

88

1 reference

2 December 2017

issue

1

1 reference

2 December 2017

page(s)

77-82

1 reference

Effects of statins on vascular wall: vasomotor function, inflammation, and plaque stability

2 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900368-6

7 January 2021

Effects of HMG-CoA reductase inhibitor on hemostasis

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900368-6

7 January 2021

HMG-CoA reductase inhibitors reduce MMP-9 secretion by macrophages

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900368-6

7 January 2021

Vastatins Inhibit Tissue Factor in Cultured Human Macrophages

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900368-6

7 January 2021

HMG CoA reductase inhibitors reduce plasminogen activator inhibitor-1 expression by human vascular smooth muscle and endothelial cells

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900368-6

7 January 2021

The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900368-6

7 January 2021

Lipid lowering promotes accumulation of mature smooth muscle cells expressing smooth muscle myosin heavy chain isoforms in rabbit atheroma

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900368-6

7 January 2021

Lipid lowering by diet reduces matrix metalloproteinase activity and increases collagen content of rabbit atheroma: a potential mechanism of lesion stabilization.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900368-6

7 January 2021

An HMG-CoA reductase inhibitor, cerivastatin, suppresses growth of macrophages expressing matrix metalloproteinases and tissue factor in vivo and in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900368-6

7 January 2021

Vascular effects of estrogen and vitamin E therapies in postmenopausal women

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900368-6

7 January 2021

Vascular effects of estrogen and cholesterol-lowering therapies in hypercholesterolemic postmenopausal women

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900368-6

7 January 2021

Vascular effects of synthetic or natural progestagen combined with conjugated equine estrogen in healthy postmenopausal women

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900368-6

7 January 2021

Effects of hormone-replacement therapy on fibrinolysis in postmenopausal women

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900368-6

7 January 2021

Vascular effects of estrogen in type II diabetic postmenopausal women

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900368-6

7 January 2021

Direct vascular effects of HMG-CoA reductase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900368-6

7 January 2021

Simvastatin has anti-inflammatory and antiatherosclerotic activities independent of plasma cholesterol lowering

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900368-6

7 January 2021

Simvastatin preserves coronary endothelial function in hypercholesterolemia in the absence of lipid lowering

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900368-6

7 January 2021

Infiltrates of activated mast cells at the site of coronary atheromatous erosion or rupture in myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900368-6

7 January 2021

Acute coronary syndromes: unstable angina and non-Q-wave myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900368-6

7 January 2021

Peripheral blood levels of matrix metalloproteases-2 and -9 are elevated in patients with acute coronary syndromes

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900368-6

7 January 2021

Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900368-6

7 January 2021

Requirement for mevalonate in acetylated LDL induction of cholesterol esterification in macrophages

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900368-6

7 January 2021

Regression of Coronary Atheromatosis in Rhesus Monkeys

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900368-6

7 January 2021

George Lyman Duff memorial lecture. Progression and regression of atherosclerotic lesions. Insights from lipid physical biochemistry.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900368-6

7 January 2021

Oxidized low-density lipoprotein regulates matrix metalloproteinase-9 and its tissue inhibitor in human monocyte-derived macrophages.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900368-6

7 January 2021

Pravastatin Has Cholesterol-Lowering Independent Effects on the Artery Wall of Atherosclerotic Monkeys

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900368-6

7 January 2021

Localization of tissue factor in the normal vessel wall and in the atherosclerotic plaque

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900368-6

7 January 2021

Oxidized LDL enhances lipopolysaccharide-induced tissue factor expression in human adherent monocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900368-6

7 January 2021

Simvastatin reduces monocyte-tissue-factor expression type IIa hypercholesterolaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900368-6

7 January 2021

Dietary lipid lowering reduces tissue factor expression in rabbit atheroma.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900368-6

7 January 2021

Association of fibrinolytic parameters with early atherosclerosis. The ARIC Study. Atherosclerosis Risk in Communities Study

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900368-6

7 January 2021

Fibrinolytic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. ECAT Study Group. European Concerted Action on Thrombosis and Disabilities

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900368-6

7 January 2021

Comparison of bezafibrate versus lovastatin for lowering plasma insulin, fibrinogen, and plasminogen activator inhibitor-1 concentrations in hyperlipemic heart transplant patients

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900368-6

7 January 2021

Elevated plasma levels of vascular endothelial cell markers in patients with hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900368-6

7 January 2021

10.1016/S0167-5273(02)00368-6

Identifiers

DOI

1 reference

2 December 2017

1 reference